Jan. 29, 2026 — The American Society for Radiation Oncology (ASTRO) has launched a national program creating Authorized User (AU) Training Centers for physicians wanting to provide radiopharmaceutical therapy. This initiative is designed to expand patient access and increase the number of physicians certified to provide the safe delivery of these emerging cancer treatments.

Jan. 22, 2026 — In breast cancer, a biopsy is the only diagnostic procedure that can determine if a suspicious lump or area is cancerous. However, in the U.S., between 75% and 80% of breast biopsies are benign.

Jan. 27, 2026 —  Researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with other leading institutions across the country, have published a new study that provides radiation oncologists with practical guidance to identify and protect female sexual organs during pelvic cancer treatment.

Jan. 27, 2026 — Hyperfine has announced results from the largest data set to date evaluating stroke detection with its Swoop portable MRI system. This data provides strong evidence supporting the use of AI-powered portable MRI for stroke detection in multiple clinical settings, including the emergency department.

Jan. 22, 2026—The American Roentgen Ray Society (ARRS) will host a live virtual symposium, "Medical Imaging for Spaceflight," examining how radiology supports astronaut health and medical decision-making in the spaceflight environment.

Jan. 27, 2026 — Siemens Healthineers and World Athletics have joined forces to inform medical teams how point-of-care testing (POCT) and diagnostic imaging can enhance athlete safety at endurance events and redefine how event medical teams support athletes and event spectators.

Jan.26, 2026 — SimonMed Imaging has unveiled an updated brand and the launch of SimonMed Longevity, a new division focused on AI-enabled preventive care and longevity screening. 

The rebrand reflects a broader strategic evolution in SimonMed’s approach to patient care, leveraging AI to expand its focus in including earlier risk identification and preventive support, alongside extensive diagnostic services. 

Jan. 027, 2026 — QT Imaging and Olea Medical have announced plans to collaborate. This collaboration enhances QT Imaging’s Cloud SaaS Platform by integrating Olea Medical’s advanced visualization, quantitative analytics and AI-ready imaging technologies to support clinical interpretation, research workflows and quantitative imaging analysis.

The Olea collaboration builds on QT Imaging’s existing cloud infrastructure, to be delivered through InteleShare platform, which provides the enterprise PACS and cloud backbone for QT Imaging’s clinical and research deployments.

Jan. 26, 2026 — Nuclidium, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, recently announced that U.S. Patent No. 12,527,885 has been granted by the United States Patent and Trademark Office (USPTO). This strengthens and extends the scope of the intellectual property portfolio for Nuclidium’s NU101 radiotheranostic program. The patent protects the Copper-61 based diagnostic as well as its use in combination with the Copper-67 based therapeutic in a theranostic setting.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now